|
Prostatic Neoplasms
|
0.400 |
Therapeutic
|
group |
CTD_human |
The mRNA levels of PPFIBP2 and ESR2 are differentially expressed in prostate tumours and paired normal tissues.
|
26443449 |
2015 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The mRNA levels of PPFIBP2 and ESR2 are differentially expressed in prostate tumours and paired normal tissues.
|
26443449 |
2015 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Expression of Sp1 and c-FLIP are elevated while AKR1C1, ERβ and Sp3 are significantly low in human prostate tumor samples.
|
25816367 |
2015 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
An inverse correlation between the expression of ERβ and IKKβ/p65 was also observed in the prostates of ERβ knockout (BERKO) mice, Gleason grade 5 prostate tumors and analysis of prostate cancer databases.
|
26450901 |
2015 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
The mRNA levels of PPFIBP2 and ESR2 are differentially expressed in prostate tumours and paired normal tissues.
|
26443449 |
2015 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The objective of this study was to examine serum estrogens and prostate tumor ERβ expression and examine their correlation with clinical and pathological parameters in African American (AA) versus Caucasian American (CA) men.
|
23658372 |
2013 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our results demonstrate that estrogens and antiestrogens affect prostate tumor growth through ERβ-mediated regulation of KLF5.
|
21487105 |
2011 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Association between estrogen and androgen receptor genes and prostate cancer risk.
|
18952763 |
2009 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Estrogen receptor beta displays cell cycle-dependent expression and regulates the G1 phase through a non-genomic mechanism in prostate carcinoma cells.
|
18607069 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
|
17932344 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Regulation and expression of human CYP7B1 in prostate: overexpression of CYP7B1 during progression of prostatic adenocarcinoma.
|
17639508 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
BPA dramatically attenuated estrogen receptor beta (ERbeta) expression; this finding was specific to prostate tumor cells in which BPA induces cellular proliferation.
|
18007998 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.
|
17503469 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-beta expression or serum hormonal profiles in men at high risk of prostate cancer.
|
17585029 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Therapeutic
|
group |
CTD_human |
Regulation and expression of human CYP7B1 in prostate: overexpression of CYP7B1 during progression of prostatic adenocarcinoma.
|
17639508 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer.
|
16921512 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Estrogen receptor beta polymorphism is associated with prostate cancer risk.
|
16551880 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
Therapeutic
|
group |
CTD_human |
Apigenin suppresses cancer cell growth through ERbeta.
|
17132221 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Apigenin suppresses cancer cell growth through ERbeta.
|
17132221 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
Therapeutic
|
group |
CTD_human |
Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer.
|
16921512 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer.
|
16921512 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
Therapeutic
|
group |
CTD_human |
[Implications of estrogens and their receptors for the development and progression of prostate cancer].
|
16220300 |
2005 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
[Implications of estrogens and their receptors for the development and progression of prostate cancer].
|
16220300 |
2005 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Thus our findings implicate ERbeta as a potential target for the treatment of prostate tumours.
|
15171712 |
2004 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus our findings implicate ERbeta as a potential target for the treatment of prostate tumours.
|
15171712 |
2004 |